Recombinant Human MAP2K1

• Cat.No.: MAP2K1-343H
• Product Overview: Recombinant Human MAP2K1 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Human
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: MAP2K1 mitogen-activated protein kinase kinase 1 [ Homo sapiens ]
• Official Symbol: MAP2K1
• Gene ID: 5604
• mRNA Refseq: NM_002755.3
• Protein Refseq: NP_002746.1
• MIM: 176872
• UniProt ID: A4QPA9

Reviews

08/01/2020

The unmatched performance of the MAP2K1 protein in both ELISA assays and protein electron microscopy structure analysis showcases its versatility and reliability in various experimental settings.

05/18/2016

The MAP2K1 protein finds extensive utility in protein electron microscopy structure analysis.

04/11/2016

With its exceptional specificity and sensitivity, it enables precise and reliable detection of target molecules, making it a valuable tool in the field of diagnostic and research applications.

Q&As

Are there ongoing clinical trials targeting MAP2K1?

Yes, there are clinical trials exploring the efficacy and safety of MAP2K1 inhibitors in various cancers and other diseases.

Are there diagnostic tests specifically targeting MAP2K1 in clinical practice?

Some diagnostic tests may analyze MAP2K1 mutations, especially in the context of cancer, to inform treatment decisions.

What diagnostic applications does MAP2K1 have in cancer detection?

MAP2K1 mutations can serve as biomarkers in cancer diagnostics, aiding in the identification and classification of tumors.

How does MAP2K1 contribute to drug resistance in cancer treatment?

MAP2K1 mutations can be associated with resistance to certain cancer therapies, making it important to understand its role in treatment response.

Are there targeted therapies based on MAP2K1 in cancer treatment?

Yes, MAP2K1 inhibitors are being explored as targeted therapies in cancer treatment, aiming to block the abnormal signaling associated with MAP2K1 mutations.